Trimel Pharmaceuticals Corporation is a unique specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders. The Corporation holds the development and marketing rights to a bioadhesive intranasal gel drug delivery technology platform and owns a novel dry power drug delivery technology platform and is actively pursuing the development and application of these technologies to products that are currently in Phase II and Phase III clinical testing. These drug delivery platforms are: (a) a bioadhesive intranasal gel and (b) a unit dose dry powder inhaler/nasal dispersion system. Trimel’s actively targeted indications include (a) male hypogonadism (low testosterone or “Low-T”), (b) female sexual dysfunction (“anorgasmia”), and (c) respiratory disorders (“asthma”), representing an annual total estimated addressable market of over $30 billion in the United States alone.

The Corporation has optimized and further developed drug delivery technology platforms that are intended to create products that are expected to be safer, more effective, easier to use and more practical than competitive products on the market. Additionally, Trimel products are being developed to precisely target the delivery of medications, thereby avoiding “first-pass” negative effects and other common side-effects associated with existing marketed products with similar indications. Since the Corporation’s inception, it has focused on the redevelopment of known high-volume pharmaceutical compounds in order to improve their performance and utilization by physicians and patients.